
SAFETY DATA SHEET

Section 1: Identification of the Product and of the Company/ Undertaking

1.1 Identification of the Product

Product Name : **DeQuanto[®] Rituximab (Mabthera[®]) PK ELISA kit**Product Code : **PK1004**

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Immunoassay for quantitative determination of Etanercept (Enbrel) drug in human serum or plasma

For research use only. Not intended for human or animal diagnostic or therapeutic uses.

1.3 Company/ Undertaking Identification

Company Name : Denovo Biolabs Private Limited
A-112, KSSIDC Block-3,
Electronic city Phase 1,
560100 BANGALORE, INDIA

Telephone No. : +91 80 29575711

Emergency No. : +91 80 29575711

Section 2: Hazards identification

2.1 GHS Classification

Signal Word: Not Hazardous**Health Hazard:** Not Hazardous**Physical Hazards:** Not Hazardous

2.2 Principle Routes of Exposure/ Potential Health effects

Eyes May cause eye irritation in susceptible persons.
Skin May cause skin irritation in susceptible persons.
Inhalation May be harmful by inhalation.
Ingestion May be harmful if swallowed.

2.3 Specific effects

Carcinogenic Effects : None
Mutagenic Effects : None
Reproductive Toxicity : None
Sensitization : None
Target Organ Effects : No known effects under normal use conditions.

HMIS

Health	0
Flammability	0
Reactivity	0

Section 3: Composition or Information on Ingredients

The product contains no substances which at their given concentration, are considered to be hazardous to health. We recommend handling all chemicals with caution.

Product Name: DeQuanto[®] Rituximab (Mabthera[®]) PK ELISA kit

Product Code: PK1004

*This Product is for Research Use only (RUO) and not to be used in Diagnostic Procedure.**Version 2.1*

DENOVO BIOLABS PVT LTD

E-mail: info@denovobiolabs.com; www.denovobiolabs.com

1X 1 Nos. Pre Coated 96-well microtiter plate

Contains ELISA plate

1X 10 µl Etanercept (Enbrel®) Standard

Contains Etanercept

1X 20 µl Detection Antibody, 2500X

Contains antibody conjugated to horse radish peroxidase.

1X 1 g Assay Diluent (Pre-mix powder)

Containing protein powder

1X 750 µl TMB Substrate, 20X

Contains TMB

1X 70 ml Wash Buffer-A, 20X

Contains Buffer with salt

1X 1 Nos. Plate sealer

For covering microtiter plate during assay run.

Section 4: First Aid Measures

Skin contact: Rinse with plenty of water. If symptoms arise, call a physician.

Eye contact: Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. If symptoms persist, call a physician.

Ingestion: Never give anything by mouth to an unconscious person. If symptoms persist, call a physician. Do not induce vomiting without medical advice.

Inhalation: Move to fresh air. If symptoms persist, call a physician. If not breathing, give artificial respiration.

Notes to physician: Treat symptomatically.

Section 5: Fire-Fighting Measures

Suitable Extinguishing Media: Water spray. Carbon dioxide (CO₂). Foam. Dry chemical.

Special protective equipment for firefighters: Wear self-contained breathing apparatus and protective suit.

Section 6: Accidental release measures

Personal precautions : Use personal protective equipment.

Methods for cleaning up : Take up mechanically and collect in suitable container for disposal.

Environmental precautions: Prevent further leakage or spillage if safe to do so.
See Section 12 for additional information.

Section 7: Handling and Storage

Handling: Always wear recommended Personal Protective Equipment. No special handling advice required.

Storage: Keep in a dry, cool and well-ventilated place.

Section 8: Exposure controls/personal protection

Exposure limits: We are not aware of any national exposure limit.

Engineering measures: Ensure adequate ventilation, especially in confined areas.

Personal protective equipment: Personal Protective Equipment requirements are dependent on the user institution's risk assessment and are specific to the risk assessment for each laboratory where this material may be used.

Respiratory protection: In case of insufficient ventilation wear suitable respiratory equipment.

Hand Protection : Impervious gloves.

Eye protection : Safety eye-glasses with side-shields.

Skin and body protection : Lightweight protective clothing.

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

Environmental exposure controls: Prevent product from entering drains.

Section 9: Physical and chemical properties

General Information

Form	:	Liquid
Appearance	:	Clear liquid
Odor	:	No data available
Boiling Point/Range	:	No data available
Melting point/Range	:	No data available
Flash point	:	Not Applicable/Aqueous Solution
Specific Gravity	:	1.010 (H ₂ O=1.0)
Water solubility	:	Soluble in water

Section 10: Stability and reactivity

Stability	: Stable under normal conditions.
Materials to avoid	: No dangerous reaction known under conditions of normal use.
Hazardous decomposition Products	: None under normal use
Polymerization	: Hazardous polymerization does not occur.

Section 11: Toxicological information

Acute toxicity : Not hazardous

Principle Routes of Exposure/ Potential Health effects:

Eyes	:	May cause eye irritation with susceptible persons
Skin	:	May cause skin irritation in susceptible persons
Inhalation	:	May be harmful by inhalation
Ingestion	:	May be harmful if swallowed
Carcinogenic Effects	:	No information available
Germ cell Mutagenicity	:	Even though this does not meet GHS classification, the following data is available: Not genotoxic based on a battery of in vitro and in vivo studies.
Reproductive toxicity	:	Even though this does not meet GHS classification, the following data is available: No increase in birth defects rate in rats or rabbits given dose 60 to 100 times the human dose.
Sensitization	:	No information available
Target Organ Effects	:	No known effects under normal use conditions.

Section 12: Ecological information

Ecotoxicity Effects	:	No information available.
Mobility	:	No information available.
Biodegradation	:	No information available.
Bioaccumulation	:	No information available.

Section 13: Disposal considerations

Dispose of in accordance with local regulations.

Section 14: Transport information

D.O.T.

Proper shipping name : None
This substance is considered non-hazardous for transport

IATA

Proper shipping name : None
This substance is considered non-hazardous for transport.

Section 15: Regulatory information

SARA 313: This product is not regulated by SARA.

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61): This product does not contain HAPs.

Product Name: DeQuanto ® Rituximab (Mabthera®) PK ELISA kit

Product Code: PK1004

This Product is for Research Use only (RUO) and not to be used in Diagnostic Procedure.

Version 2.1

U.S. State Regulations:

California Proposition 65: This product does not contain chemicals listed under Proposition 65.

WHMIS Hazard Class: Non-controlled

This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Section 16: Other information

For research use only. Not intended for human or animal diagnostic or therapeutic uses.

The above information was acquired by diligent search and/or investigation and the recommendations are based on prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.

Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held liable for any damages or losses resulting from the handling or from contact with the product as described herein.

THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.

End of Safety Data Sheet